Amylyx Pharmaceuticals, Inc. $AMLX Position Increased by Vanguard Group Inc.

Vanguard Group Inc. grew its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 17.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,273,750 shares of the company’s stock after buying an additional 775,722 shares during the quarter. Vanguard Group Inc. owned approximately 5.91% of Amylyx Pharmaceuticals worth $71,670,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Profund Advisors LLC purchased a new stake in shares of Amylyx Pharmaceuticals in the 3rd quarter valued at approximately $182,000. AlphaQuest LLC purchased a new position in Amylyx Pharmaceuticals during the 3rd quarter worth approximately $185,000. Federated Hermes Inc. grew its position in Amylyx Pharmaceuticals by 4.1% during the 3rd quarter. Federated Hermes Inc. now owns 212,379 shares of the company’s stock worth $2,886,000 after purchasing an additional 8,449 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Amylyx Pharmaceuticals during the 3rd quarter valued at $333,000. Finally, SG Americas Securities LLC acquired a new stake in Amylyx Pharmaceuticals during the 3rd quarter valued at $161,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

More Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised near-term quarterly EPS forecasts (now -$0.34 per quarter in 2026 vs prior deeper losses) and materially boosted multi‑year outlook (FY2029 and FY2030 upgrades) while maintaining a “Buy” rating and a $34 price objective — a clear vote of confidence on longer‑term upside.
• Positive Sentiment: Avexitide remains the company’s key near‑term catalyst: Phase 3 LUCIDITY topline data due Q3 2026; management is viewed as well‑funded (reported cash runway cited ~ $317M into 2028), which supports commercialization planning if results are positive. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
• Positive Sentiment: New coverage initiated by Stifel Nicolaus can increase visibility and institutional interest, a constructive development for liquidity and analyst debate. Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated at Stifel Nicolaus
• Neutral Sentiment: Q4 2025 earnings call highlighted strategic advances and the company slightly beat EPS expectations (reported -$0.30 vs -$0.31 consensus), but near‑term profitability remains a multi‑quarter issue. Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest reports in the filings provided show zero or nonsensical values (likely reporting artifacts) and so offer no clear signal on current positioning.
• Negative Sentiment: Management discontinued development of AMX0035 for progressive supranuclear palsy (PSP), narrowing the near‑term pipeline and prompting at least one downgrade (from “Strong Buy” to “Buy”); loss of a program can reduce optionality and may weigh on sentiment until avexitide data arrives. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 1,995 shares of the company’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $13.89, for a total value of $27,710.55. Following the transaction, the chief executive officer directly owned 3,379,398 shares of the company’s stock, valued at $46,939,838.22. This represents a 0.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Joshua B. Cohen sold 1,974 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $13.83, for a total value of $27,300.42. Following the sale, the chief executive officer directly owned 3,379,465 shares of the company’s stock, valued at $46,738,000.95. This trade represents a 0.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 151,203 shares of company stock worth $2,028,385 in the last ninety days. Company insiders own 12.30% of the company’s stock.

Analyst Upgrades and Downgrades

AMLX has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. HC Wainwright upped their price target on Amylyx Pharmaceuticals from $28.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday. Bank of America increased their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $21.00 price objective for the company. Finally, Wall Street Zen raised Amylyx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.56.

Amylyx Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ:AMLX opened at $13.85 on Friday. The firm has a fifty day moving average of $13.94 and a two-hundred day moving average of $13.22. The firm has a market capitalization of $1.53 billion, a P/E ratio of -8.94 and a beta of -0.31. Amylyx Pharmaceuticals, Inc. has a 12-month low of $3.11 and a 12-month high of $17.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. Equities research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.